Drugs / 64Cu-GRIP B
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07481136 | Aug 2026 → Nov 2030 expected | acute myocarditis | Javid Moslehi, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06522932 | Oct 2024 → Jan 2027 expected | non-Hodgkin lymphoma | Michael Randall | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-GRIP B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06522932 ↗ |
| Modality | Diagnostic / imaging agent | “64Cu-GRIP B, a Radiotracer Targeting Granzyme B” NCT06522932 ↗ |
| Route | Intravenous | “Given IV” NCT06522932 ↗ |